Madhya Pradesh-based Jiwaji University and Delhi-based AIMIL Pharmaceutical firm have inked an MoU to develop new Ayurveda drugs using nanotechnology.
The pact is also aimed at standardising and scientifically validating the existing drug formulations in the ayurveda sector.
Former health secretary and ex-Director General of Indian Council of Medical Research, Dr V M Katoch, who was present at the MoU signing function, lauded the improved co-ordination between research institutes and ayurvedic industry.
The MoU was signed between Jiwaji University Vice-Chancellor, Dr Sangeeta Shukla and AIMIL Pharmaceutical Executive Director Sanchit Sharma.
"Ayurveda is the key to treating some of the incurable diseases. If old formulations are subjected to modern research, we will surely be able to develop world-class medicines with negligible side effects," Dr Katoch said.
Commenting on the development, AIMIL Pharmaceuticals (I) Ltd Executive Director Sanchit Sharma said, "AIMIL will pump in resources, like equipment and technology inputs, to help the University utilise its pool of qualified researchers to its optimal potential."
Disclaimer: No Business Standard Journalist was involved in creation of this content